Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacoeconomic analysis of tenofovir amibufenamide versus entecavir in chronic hepatitis B
ChiCTR2500097387Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Feb 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir + amibufenamide and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: HBV-DNA negative conversion rate at 48 weeks. Started Feb 2025; status: completed.
02
Drugs
tenofovir + amibufenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500097387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097387.